|Last Update: 05/23/13 - 3:35 PM EDT|
|YTD Performance: 40.63%|
|Previous Close: $42.70|
|52 Week Range: $20.72 - $48.59|
|Oustanding Shares: 94,258,327|
|Market Cap: 4,074,787,476|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||13||13||14||14|
|Growth Rate (Year over Year)||3.39%||4.11%||3.90%||25.87%|
Shares of CYH now seen reaching $55, according to Credit Suisse. Estimates also increased, given better pricing and cost controls. Outperform rating.
CYH was upgraded from Neutral to Outperform, Robert Baird said. $56 price target. Stock has pulled back 15% from its recent highs.
CYH was downgraded from Buy to Hold, Deutsche Bank said. Higher health insurance coverage is largely priced into the sector.
CYH was upgraded from Hold to Buy, Jefferies said. $56 price target. Hospital industry should benefit from healthcare reform.
CYH was downgraded to Underperform from Market Perform, BMO Capital Markets said. $35 price target. Near term downside risk leaves shares less attractive.
CYH was upgraded to Buy from Neutral, Bank of America Merrill Lynch said. $45 price target. Reform positives clear and story is de risked.
A look at the different sectors that will be affected by a reelection.
Shares of CYH now seen reaching $29, Jefferies said. Easy 2H12 comps and discounted valuation could ignite upward momentum. Hold rating.
Portfolio Manager David Peltier discusses how the recent pop in this low-dollar hospital operator.
If the healthcare plan stands, these names stand to reap rich rewards.